While some improvement was achieved by the addition of etoposide and shortening the treatment intervals from 3 to 2 weeks , the best results in young, good-prognosis patients [age-adjusted (aa) International Prognostic Index (IPI) 0, 1] have been achieved with six cycles of a CHOP-like chemotherapy in combination with the anti-CD20 antibody rituximab. The role of additional radiotherapy in this setting remains to be determined. With this approach, 2-year event-free survival rates of >90% and overall survival of >95% can be achieved in a very favorable subgroup (patients without IPI risk factor and no bulky disease), while further improvement is warranted for the less favorable subgroup (event-free survival only 77%).
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For young poor-prognosis patients (aaIPI > _ 2), the 5-year survival is 50%, and progress has not been convincingly and specifically demonstrated in these patients. Ongoing studies will show whether dose-dense conventional or high-dose chemotherapy regimens requiring stem cell support in combination with rituximab will result in similar improvements of outcome, as has been reported recently for young patients with good-prognosis aggressive lymphoma.
In elderly patients, interval reduction of CHOP from 3 to 2 weeks (CHOP-14) and addition of rituximab to CHOP-21 achieved similar improvements in outcome. The ongoing RICOVER-60 trial of the DSHNHL evaluates whether the combination of the two approaches (R-CHOP-14) can further improve the prognosis of elderly patients.
Gene analysis of tumor burden may indicate patient prognosis more precisely than the IPI score, but prospective trials are required to find the optimal treatment for each patient. 
